You are here:
Home
NICE Guidance
Conditions and diseases
Cancer
Bladder cancer
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]
Awaiting development
Reference number:
GID-TA11556
Expected publication date: TBC
Project information
Project documents
38268-Pembrolizumab-for-Urothelial-Carcinoma-V1.0-MAR2024-NON-CONF.pdf (nihr.ac.uk)
Back to top